Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial
Authors
Keywords
-
Journal
LANCET INFECTIOUS DISEASES
Volume 22, Issue 3, Pages 329-340
Publisher
Elsevier BV
Online
2021-11-24
DOI
10.1016/s1473-3099(21)00677-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial
- (2021) Cassandra Aldrich et al. VACCINE
- Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
- (2021) Wilfredo F. Garcia-Beltran et al. CELL
- The emergence of new strains of SARS-CoV-2. What does it mean for COVID-19 vaccines?
- (2021) Md Kamal Hossain et al. Expert Review of Vaccines
- Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
- (2021) Katherine R W Emary et al. LANCET
- Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
- (2021) Shabir A. Madhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
- (2021) Jerald Sadoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
- (2021) Vivek Shinde et al. NEW ENGLAND JOURNAL OF MEDICINE
- mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents
- (2021) Susanne Rauch et al. npj Vaccines
- Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals
- (2021) Talia Kustin et al. NATURE MEDICINE
- Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
- (2021) Paul T. Heath et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2
- (2021) Peter G. Kremsner et al. WIENER KLINISCHE WOCHENSCHRIFT
- The promise of mRNA vaccines: a biotech and industrial perspective
- (2020) Nicholas A. C. Jackson et al. npj Vaccines
- COVID-19 related reduction in pediatric emergency healthcare utilization – a concerning trend
- (2020) Christian Dopfer et al. BMC Pediatrics
- Excess Deaths From COVID-19 and Other Causes, March-July 2020
- (2020) Steven H. Woolf et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
- (2020) Merryn Voysey et al. LANCET
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- mRNA vaccines — a new era in vaccinology
- (2018) Norbert Pardi et al. NATURE REVIEWS DRUG DISCOVERY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More